Abstract
Ferumoxytol across the age spectrum: a single center experience of safety
Highlights
Ferumoxytol is used for parenteral iron therapy in patients with chronic kidney disease (CKD)
Type and severity of adverse reactions to ferumoxytol as an MRI contrast agent over a broad spectrum of ages and indications in a single center study
First pass and steady state ferumoxytol enhanced MRA (FEMRA) were performed in 119 patients and 46 patients had only steady state imaging
Summary
Ferumoxytol is used for parenteral iron therapy in patients with chronic kidney disease (CKD). Because of its uniquely powerful properties as an intravascular MR contrast agent, there is growing interest in the safety of ferumoxytol as a possible alternative to gadoliniumbased contrast agents in patients with CKD and in patients with congenital heart disease. Type and severity of adverse reactions to ferumoxytol as an MRI contrast agent over a broad spectrum of ages and indications in a single center study
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
